P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

Abstract : TP53 also known as p53 is a tumor suppressor gene mutated in a variety of cancers. P53 is involved in cell cycle, apoptosis and DNA repair mechanisms and is thus tightly controlled by many regulators. Recently, strategies to treat cancer have focused on the development of MDM2 antagonists to induce p53 stabilization and restore cell death in p53 non-mutated cancers. However, some of these molecules display adverse effects in patients including induction of thrombocytopenia. In the present study, we have explored the effect of SAR405838 not only on human megakaryopoiesis but also more generally on hematopoiesis. We compared its effect to MI-219 and Nutlin, which are less potent MDM2 antagonists than SAR405838. We found that all these compounds induce a deleterious effect on all types of hematopoietic progenitors, as well as on erythroid and megakaryocytic differentiation. Moreover, they inhibit both early and late stages of megakaryopoiesis including ploidization and proplatelet formation. In conclusion, MDM2 antagonists induced a major hematopoietic defect in vitro as well as an inhibition of all stages of megakaryopoiesis that may account for in vivo thrombocytopenia observed in treated patients.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2016, 7, pp.31980-92. 〈10.18632/oncotarget.7881〉
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

Contributeur : Institut Pasteur Tunis <>
Soumis le : mardi 14 février 2017 - 15:25:47
Dernière modification le : jeudi 11 octobre 2018 - 17:06:01


P53 activation.pdf
Publication financée par une institution


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License



Emna Mahfoudhi, Larissa Lordier, Caroline Marty, Jiajia Pan, Anita Roy, et al.. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.. Oncotarget, Impact journals, 2016, 7, pp.31980-92. 〈10.18632/oncotarget.7881〉. 〈pasteur-01467563〉



Consultations de la notice


Téléchargements de fichiers